Dermatology World March 2011 : Page 21
tment is back! The Calcipotriene Ointment , 0.005% Bioequivalent to Dovonex®* ointment Prescribing flexibility -not a combination agent From Taro Pharmaceuticals, a leader in topical dermatologics Available generically -cost effective Safety Information: In controlled clinical trials, the most frequent adverse reactions reported for calcipotriene were burning, itching and skin irritation, which occurred in approximately 10 -15% of patients. Erythema, dry skin, peeling, rash, dermatitis, worsening of psoriasis including development of facial/scalp psoriasis were reported in 1-10% of patients. Other experiences reported in less than 1% of patients included skin atrophy, hyperpigmentation, hypercalcemia, and folliculitis. Once daily dosing has not been shown to be superior in safety to twice daily dosing. Calcitrene™ is contrain-dicated in those patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcitrene™ should not be used on the face. Use of calcipotriene may cause irritation of lesions and surrounding uninvolved skin. If irritation develops, calcipotriene should be discontinued. Please see next page for complete Prescribing Information. *Dovonex® is a registered trademark of LEO PHARMA A/S CORPORATION Taro Pharmaceuticals U.S.A., Inc. All rights reserved TaroPharma® and Calcitrene™ are trademarks of Taro Pharmaceuticals U.S.A., Inc. and/or its affiliates. December 2010 AD930-0006-21 For Free Samples, Call: 877-388-5621 ent is back! The Calcipotriene Ointment , 0.005% Bioequivalent to Dovonex®* ointment Prescribing flexibility - not a combination agent From Taro Pharmaceuticals, a leader in topical dermatologics Available generically - cost effective Safety Information: In controlled clinical trials, the most frequent adverse reactions reported for calcipotriene were burning, itching and skin irritation, which occurred in approximately 10 -15% of patients. Erythema, dry skin, peeling, rash, dermatitis, worsening of psoriasis including development of facial/scalp psoriasis were reported in 1-10% of patients. Other experiences reported in less than 1% of patients included skin atrophy, hyperpigmentation, hypercalcemia, and folliculitis. Once daily dosing has not been shown to be superior in safety to twice daily dosing. Calcitrene™ is contrain-dicated in those patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcitrene™ should not be used on the face. Use of calcipotriene may cause irritation of lesions and surrounding uninvolved skin. If irritation develops, calcipotriene should be discontinued. Please see next page for complete Prescribing Information. *Dovonex® is a registered trademark of LEO PHARMA A/S CORPORATION Taro Pharmaceuticals U.S.A., Inc. All rights reserved TaroPharma® and Calcitrene™ are trademarks of Taro Pharmaceuticals U.S.A., Inc. and/or its affiliates. December 2010 AD930-0006-21 For Free Samples, Call: 877-388-5621 TM TM Calcipotriene Oin It’s about time for Plaque Psoriasis New
